The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?
Joanna Mangana
Honoraria - LA ROCHE POSAY
Simone M. Goldinger
No relevant relationships to disclose
Katja Schindler
Honoraria - Bristol-Myers Squibb
Sima Rozati
Employment or Leadership Position - Research Fellow
Anna L. Frauchiger
No relevant relationships to disclose
Markus Rechsteiner
Research Funding - Roche
Holger Moch
Research Funding - Roche
Emanuela Romano
Honoraria - Bristol-Myers Squibb
Katharina C. Kaehler
Honoraria - Bristol-Myers Squibb
Olivier Michielin
No relevant relationships to disclose
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Christoph Hoeller
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Reinhard Dummer
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb; Roche